David Risinger
Stock Analyst at Leerink Partners
(3.57)
# 858
Out of 4,976 analysts
169
Total ratings
65.17%
Success rate
14.22%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $178.13 | -14.11% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $395.25 | +27.26% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $558.44 | +49.34% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $209.79 | -1.81% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.72 | +56.25% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $16.31 | +323.05% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $6.08 | +163.16% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $15.80 | +178.48% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $32.41 | +372.08% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $13.92 | -28.16% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $2.10 | -4.76% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $22.19 | +111.81% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $280.19 | +13.49% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $18.03 | -38.99% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $738.64 | -37.99% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $75.85 | -44.63% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $115.88 | -21.47% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.55 | +95.52% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $12.91 | -22.54% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $10.47 | +253.39% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $129.85 | +35.54% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.48 | +52.67% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $22.33 | +101.52% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.33 | +377.49% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $19.05 | +115.22% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $151.75 | +14.66% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $35.80 | +42.46% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $19.30 | -58.55% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $84.09 | +5.84% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $9.73 | -69.17% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $28.45 | -43.76% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $178.13
Upside: -14.11%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $395.25
Upside: +27.26%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $558.44
Upside: +49.34%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $209.79
Upside: -1.81%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.72
Upside: +56.25%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $16.31
Upside: +323.05%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $6.08
Upside: +163.16%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $15.80
Upside: +178.48%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $32.41
Upside: +372.08%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $13.92
Upside: -28.16%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $2.10
Upside: -4.76%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $22.19
Upside: +111.81%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $280.19
Upside: +13.49%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $18.03
Upside: -38.99%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $738.64
Upside: -37.99%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $75.85
Upside: -44.63%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $115.88
Upside: -21.47%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.55
Upside: +95.52%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $12.91
Upside: -22.54%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $10.47
Upside: +253.39%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $129.85
Upside: +35.54%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.48
Upside: +52.67%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $22.33
Upside: +101.52%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.33
Upside: +377.49%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $19.05
Upside: +115.22%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $151.75
Upside: +14.66%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $35.80
Upside: +42.46%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $19.30
Upside: -58.55%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $84.09
Upside: +5.84%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $9.73
Upside: -69.17%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $28.45
Upside: -43.76%